These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 15180459)
21. Synthesis and antibacterial activity of quinolone-based compounds containing a coumarin moiety. Emami S; Foroumadi A; Faramarzi MA; Samadi N Arch Pharm (Weinheim); 2008 Jan; 341(1):42-8. PubMed ID: 18072241 [TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of modified quinolones as antitumoral acridones. Tabarrini O; Cecchetti V; Fravolini A; Nocentini G; Barzi A; Sabatini S; Miao H; Sissi C J Med Chem; 1999 Jun; 42(12):2136-44. PubMed ID: 10377219 [TBL] [Abstract][Full Text] [Related]
23. Prospects for developing new antibacterials targeting bacterial type IIA topoisomerases. Tomašić T; Mašič LP Curr Top Med Chem; 2014; 14(1):130-51. PubMed ID: 24236722 [TBL] [Abstract][Full Text] [Related]
24. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Anderson VE; Osheroff N Curr Pharm Des; 2001 Mar; 7(5):337-53. PubMed ID: 11254893 [TBL] [Abstract][Full Text] [Related]
25. Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones. Malik M; Zhao X; Drlica K Mol Microbiol; 2006 Aug; 61(3):810-25. PubMed ID: 16803589 [TBL] [Abstract][Full Text] [Related]
27. 5-Amino-7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6,8-difluoro-1,4- dihydro-4-oxo-3-quinolinecarboxylic acid (PD 124,816). Synthesis and biological evaluation of a new class of quinolone antibacterials. Domagala JM; Hagen SE; Hutt MP; Sanchez JP; Sesnie J; Trehan AK Drugs Exp Clin Res; 1988; 14(7):453-60. PubMed ID: 2853667 [TBL] [Abstract][Full Text] [Related]
28. Fluoroquinolone-dependent DNA supercoiling by Vaccinia topoisomerase I. Kamau E; Grove A J Mol Biol; 2004 Sep; 342(2):479-87. PubMed ID: 15327948 [TBL] [Abstract][Full Text] [Related]
31. Recent advances in the discovery and development of quinolones and analogs as antitumor agents. Xia Y; Yang ZY; Morris-Natschke SL; Lee KH Curr Med Chem; 1999 Mar; 6(3):179-94. PubMed ID: 10219099 [TBL] [Abstract][Full Text] [Related]
32. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Strahilevitz J; Hooper DC Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518 [TBL] [Abstract][Full Text] [Related]
33. 6-Aminoquinolones as new potential anti-HIV agents. Cecchetti V; Parolin C; Moro S; Pecere T; Filipponi E; Calistri A; Tabarrini O; Gatto B; Palumbo M; Fravolini A; Palu' G J Med Chem; 2000 Oct; 43(20):3799-802. PubMed ID: 11020296 [TBL] [Abstract][Full Text] [Related]
35. Stereo (C7)-dependent topoisomerase II inhibition and tumor growth suppression by a new quinolone, BO-2367. Yoshinari T; Mano E; Arakawa H; Kurama M; Iguchi T; Nakagawa S; Tanaka N; Okura A Jpn J Cancer Res; 1993 Jul; 84(7):800-6. PubMed ID: 8396568 [TBL] [Abstract][Full Text] [Related]
36. QSAR study and VolSurf characterization of anti-HIV quinolone library. Filipponi E; Cruciani G; Tabarrini O; Cecchetti V; Fravolini A J Comput Aided Mol Des; 2001 Mar; 15(3):203-17. PubMed ID: 11289075 [TBL] [Abstract][Full Text] [Related]
37. Quinolone mode of action--new aspects. Hooper DC Drugs; 1993; 45 Suppl 3():8-14. PubMed ID: 7689456 [TBL] [Abstract][Full Text] [Related]